Semaglutide
Approvedaka Ozempic, Wegovy, Rybelsus
Approved GLP-1 agonist. The drug that kicked off the whole weight-loss gold rush.
Mechanism
Copies the gut hormone GLP-1: slows your stomach down, kills appetite, and tightens up insulin response. Simple mechanism, huge results, which is why it's everywhere.
Regulatory & Safety Status
Approved: Ozempic and Rybelsus for diabetes, Wegovy for obesity. Get it prescribed. The compounded and grey-market stuff is where dosing accidents happen.
Research
Current status of anti-obesity medications and performance, an EHR based survey
Articles You Might Have Missed
Real-World Semaglutide Initiation Behaviours in the United States: Impact on Early Treatment Discontinuation and on 1-Year Persistence
Changes in Muscle Strength Following Semaglutide Treatment in Adults: A Systematic Review With Meta-Analysis of Handgrip Strength
STEP 1 weight management trial
Latest semaglutide research
In the News
FDA confirms semaglutide and tirzepatide off the drug shortage list
Supply is back, so the compounding pharmacies lose the shortage exemption. If you have been getting cheap compounded semaglutide, that tap is closing.
FDA warns consumers against unapproved and compounded GLP-1 products
The agency is flagging dosing mistakes and quality problems with compounded and counterfeit versions. Know your source, or skip it.
GLP-1 demand keeps obesity drugs the dominant pharma growth story
Capacity expansions and the next wave of triple-agonists keep obesity drugs the biggest story in pharma.